Brazil’s plan for low-cost CAR-Ts

New biotech newsletter launching tomorrow. Don’t miss out.

Good morning, everyone. Damian here with the details on a potentially major drug approval, an idea to make CAR-T more equitable, and the slow launch of a gene therapy.

The need-to-know this morning

• Blackstone Life Sciences said it will invest up to $750 million to support Moderna’s mRNA-based flu vaccine programs.
• The European academic “TUDCA” study in ALS failed to its primary goal of slowing disease progression. The study was designed to investigate one of the two drug ingredients in Amylyx Pharma’s Relyvrio, which also recently failed its own clinical trial.

Merck’s potential blockbuster gets a clean label

The FDA approved Merck’s new treatment for a rare cardiovascular disease yesterday, clearing a drug that could bring in nearly $5 billion a year at its peak.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In